Summary
Intuitive Surgical Inc. (ISRG) reported strong performance for the second quarter and first half of 2017, demonstrating continued growth in both revenue and procedure volume. Total revenue increased by 13% year-over-year in the second quarter, driven by a 15% increase in recurring revenue, which now represents 71% of total revenue. This growth is largely attributed to a 16% increase in da Vinci procedures performed during the quarter, highlighting the increasing adoption and utilization of the da Vinci Surgical System. The company also saw a 7% increase in systems revenue, with a notable 34% rise in system shipments compared to the prior year period, suggesting expanding market penetration. Financially, the company maintained healthy profitability with gross profit margins around 70% and saw operating income increase by 5%. Despite a significant $2.0 billion accelerated share repurchase program in the first quarter, the company maintained a robust cash position of $3.4 billion in cash, cash equivalents, and investments as of June 30, 2017. Management expressed confidence in their ability to fund future growth through operating cash flows. The company also introduced the new da Vinci X Surgical System in May 2017, which is expected to enhance market reach and affordability.
Financial Highlights
46 data points| Revenue | $758.80M |
| Cost of Revenue | $228.70M |
| Gross Profit | $530.10M |
| R&D Expenses | $84.60M |
| SG&A Expenses | $185.60M |
| Operating Expenses | $270.20M |
| Operating Income | $259.90M |
| Net Income | $223.00M |
| EPS (Basic) | $0.67 |
| EPS (Diluted) | $0.65 |
| Shares Outstanding (Basic) | 333.00M |
| Shares Outstanding (Diluted) | 345.60M |
Key Highlights
- 1Total revenue for Q2 2017 increased by 13% to $756.2 million, driven by strong recurring revenue growth.
- 2Instrument and accessory revenue (recurring revenue) increased by 17% to $397.8 million, now comprising 71% of total revenue.
- 3Da Vinci procedures performed grew by 16% in Q2 2017, indicating increasing adoption and utilization of the company's surgical systems.
- 4System shipments increased by 34% to 166 units in Q2 2017, with the installed base growing by 11% year-over-year to approximately 4,149 systems.
- 5Gross profit margin remained strong at approximately 70% for both product and total revenue.
- 6The company maintained a substantial liquidity position with $3.4 billion in cash, cash equivalents, and investments as of June 30, 2017.
- 7Introduction of the da Vinci X Surgical System in May 2017, offering advanced technology at a more accessible price point.